Imipenem/cilastatin in the treatment of obstetric and gynecologic infections: a review of worldwide experience.
Worldwide experience with imipenem/cilastatin in the treatment of 72 patients with a variety of obstetric and gynecologic infections is reviewed. Clinical cure or improvement occurred in 97% of 72 assessable patients. The most common etiologic pathogens were Escherichia coli, group B streptococci, Neisseria gonorrhoeae, Staphylococcus epidermidis, enterococci, Bacteroides bivius, Bacteroides species, Bacteroides fragilis, and Peptostreptococcus. Of the recovered pathogens, 99.5% were susceptible to imipenem/cilastatin. Bacteriologic response was also excellent and none of the pathogens acquired resistance to imipenem. Most patients tolerated intravenous administration of imipenem/cilastatin well to moderately well.
D000038:Abscess / Q000188:drug therapy; D000293:Adolescent; D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D015377:Cilastatin; D002986:Clinical Trials as Topic; D003521:Cyclopropanes / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D004716:Endometritis / Q000188:drug therapy; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D015378:Imipenem; D008875:Middle Aged; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy; D011247:Pregnancy; D013845:Thienamycins / Q000008:administration & dosage*
D003521:Cyclopropanes; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem